University Hospital, Basel, Switzerland
usb.chLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
976
Active
212
Phase 3
37
Total enrollment
857,947
Pipeline matrix
Showing 40 of 67 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Prednisone | — | — | — | — | 6 | ||
| Empagliflozin 25 MG | — | — | — | — | — | 1 | |
| Lorazepam 1 mg | — | — | — | — | — | 1 | |
| Immune checkpoint inhibitors plus Iscador® Qu. | — | — | — | — | — | 1 | |
| Immune Checkpoint Inhibitors | — | — | — | — | — | 1 | |
| intravesical instillation with HA-CS | — | — | — | — | — | 1 | |
| intravesical instillation of sterile purified water | — | — | — | — | — | 1 | |
| Cabergoline | — | — | — | — | — | 1 | |
| Wilate | — | — | — | — | — | 1 | |
| Melatonin | — | — | — | — | 2 | ||
| Metamizole | — | — | — | — | 3 | ||
| Canakinumab | — | — | — | — | 3 | ||
| Colchicine | — | — | — | — | — | 1 | |
| IMP Levodopa 100mg/Carbidopa 25mg | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| DEB-DoxNic-TACE | — | — | — | — | — | 1 | |
| current standard of care | — | — | — | — | — | 1 | |
| Oxytocin nasal spray | — | — | — | — | — | 2 | |
| Lysergic Acid Diethylamide | — | — | — | — | 4 | ||
| indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor | — | — | — | — | — | 1 | |
| 61Cu-NODAGA-LM3 | — | — | — | — | — | 1 | |
| 177Lu-DOTA-JR11 | — | — | — | — | — | 1 | |
| 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4 | — | — | — | — | — | 1 | |
| TILs（Tumor Infiltrating Lymphocytes） | — | — | — | — | — | 1 | |
| Intranasal OXT | — | — | — | — | — | 1 | |
| Lysergic Acid Diethylamide Tartrate | — | — | — | — | — | 1 | |
| IFN-γ positive selected T-cells | — | — | — | — | — | 1 | |
| FLU or CZO as continuous | — | — | — | — | — | 1 | |
| standard FLU or CZO intermittent bolus administration | — | — | — | — | — | 1 | |
| Nintedanib | — | — | — | — | — | 1 | |
| Donor-derived ex-vivo expanded EBV Tscm CTL | — | — | — | — | — | 1 | |
| N-TEC | — | — | — | — | — | 1 | |
| Platelet rich plasma | — | — | — | — | — | 1 | |
| Engineered cartilage graft | — | — | — | — | — | 1 | |
| LSD | — | — | 11 | ||||
| Psilocybin | — | — | — | — | 5 | ||
| 177Lu-PP-F11N | — | — | — | — | 2 | ||
| DMT | — | — | — | — | — | 1 | |
| Experimental Intervention | — | — | — | — | — | 1 | |
| Ketanserin 40mg plus Psilocybin 40mg | — | — | — | — | — | 1 |
27 more active programs hidden
Next readouts
- 2024-08-27
- 2025-05-04
- 2025-06
- 2025-12
- 2025-12
- 2026-04
- 2026-05-31
- 2026-05-31
- 2026-08
- 2026-08-01
Top conditions
- Healthy48
- Obesity15
- Multiple Sclerosis10
- Atrial Fibrillation10
- Breast Cancer9
- Pain9
- Glaucoma9
- Hyponatremia8
Frequently asked questions about University Hospital, Basel, Switzerland
- How many clinical trials does University Hospital, Basel, Switzerland have on ClinicalTrials.gov?
- University Hospital, Basel, Switzerland is listed as the lead sponsor on 976 clinical trials in ClinicalTrials.gov, 212 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Basel, Switzerland's trials are in Phase 3?
- 37 of University Hospital, Basel, Switzerland's trials are in Phase 3, spread across 67 active drug programs.
- What therapeutic areas does University Hospital, Basel, Switzerland focus on?
- University Hospital, Basel, Switzerland's most-studied conditions on ClinicalTrials.gov are Healthy, Obesity, Multiple Sclerosis, Atrial Fibrillation, Breast Cancer.
- When are University Hospital, Basel, Switzerland's next clinical trial readouts?
- University Hospital, Basel, Switzerland has 10 upcoming primary-completion readouts tracked here; the soonest is “Enhancement of Stroke Rehabilitation With Levodopa”, expected around 2024-08-27.